Functionality of HDL particles: Heterogeneity and relationships to cardiovascular disease

Archives of Cardiovascular Diseases Supplements

Volumn 3, Issue 4, 2011, Pages 258-266

  Camont, L ^a,b   Chapman, J ^a,b,c   Kontush, A ^a,b,c  

^a INSERM   (France)

^b SORBONNE UNIVERSITÉ   (France)

^c ASSISTANCE PUBLIQUE HÔPITAUX DE PARIS   (France)

Author keywords

Atherosclerosis; Biological activity; Dysfunction; Function; High density lipoprotein; Subpopulations

Indexed keywords

HIGH DENSITY LIPOPROTEIN;

ANTIINFLAMMATORY ACTIVITY; ANTIOXIDANT ACTIVITY; ARTICLE; BIOLOGICAL ACTIVITY; CARDIOVASCULAR DISEASE; CELL PROTECTION; CHOLESTEROL BLOOD LEVEL; CHOLESTEROL TRANSPORT; DISEASE ASSOCIATION; HEART PROTECTION; HUMAN; ISCHEMIC HEART DISEASE; LIPID COMPOSITION; LIPID METABOLISM; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN METABOLISM; PROTEIN STRUCTURE; RISK FACTOR; VASODILATATION;

EID: 84856460417     PISSN: 18786480     EISSN: 18786502     Source Type: Journal    
DOI: 10.1016/S1878-6480(11)70784-4     Document Type: Article

References (95)

1. Gotto A.M., Brinton E.A. Assessing low levels of high-density lipoprotein cholesterol as a risk factor in coronary heart disease: a working group report and update. J Am Coll Cardiol 2004, 43:717-724.
2. Kontush A., Chapman M.J. Functionally defective HDL: A new therapeutic target at the crossroads of dyslipidemia, inflammation and atherosclerosis. Pharmacol. Rev 2006, 3:342-374.
3. Huang R., Silva R.A., Jerome W.G., Kontush A., Chapman M.J., Curtiss L.K., et al. Apolipoprotein A-I structural organization in high-density lipoproteins isolated from human plasma. Nat Struct Mol Biol 2011, 18:416-422.
4. Rothblat G.H., Phillips M.C. High-density lipoprotein heterogeneity and function in reverse cholesterol transport. Curr Opin Lipidol 2010, 21:229-238.
5. Chapman M.J., Le Goff W., Guerin M., Kontush A. Cholesteryl ester transfer protein: at the heart of the action of lipid-modulating therapy with statins, fibrates, niacin, and cholesteryl ester transfer protein inhibitors. Eur Heart J 2010, 31:149-164.
6. Santamarina-Fojo S., Gonzalez-Navarro H., Freeman L., Wagner E., Nong Z. Hepatic lipase, lipoprotein metabolism, and atherogenesis. Arterioscler Thromb Vasc Biol 2004, 24:1750-1754.
7. Rosenson R.S., Brewer H.B., Chapman M.J., Fazio S., Hussain M.M., Kontush A., et al. HDL measures, particle heterogeneity, proposed nomenclature, and relation to atherosclerotic cardiovascular events. Clin Chem 2011, 57:392-410.
8. Vaisar T., Pennathur S., Green P.S., Gharib S.A., Hoofnagle A.N., Cheung M.C., et al. Shotgun proteomics implicates protease inhibition and complement activation in the antiinflammatory properties of HDL. J Clin Invest 2007, 117:746-756.
9. Davidson W.S., Silva R.A., Chantepie S., Lagor W.R., Chapman M.J., Kontush A. Proteomic analysis of defined HDL subpopulations reveals particle-specific protein clusters: relevance to antioxidative function. Arterioscler Thromb Vasc Biol 2009, 29:870-876.
10. Kontush A., Therond P., Zerrad A., Couturier M., Négre-Salvayre A., de Souza J.A., et al. Preferential sphingosine-1-phosphate enrichment and sphingomyelin depletion are key features of small dense HDL3 particles: relevance to antiapoptotic and antioxidative activities. Arterioscler Thromb Vasc Biol 2007, 27:1843-1849.
11. Kontush A., Chantepie S., Chapman M.J. Small, dense HDL particles exert potent protection of atherogenic LDL against oxidative stress. Arterioscler Thromb Vasc Biol 2003, 23:1881-1888.
12. Kontush A., Chapman M.J. Antiatherogenic small, dense HDL - guardian angel of the arterial wall?. Nat Clin Pract Cardiovasc Med 2006, 3:144-153.
13. Heinecke J.W. The HDL proteome: a marker-and perhaps mediator-of coronary artery disease. J. Lipid Res 2009, 50:S167-S171.
14. Gordon S., Durairaj A., Lu J.L., Davidson W.S. High-Density Lipoprotein Proteomics: Identifying New Drug Targets and Biomarkers by Understanding Functionality. Curr Cardiovasc Risk Rep 2010, 4:1-8.
15. Gordon S.M., Deng J., Lu L.J., Davidson W.S. Proteomic characterization of human plasma high density lipoprotein fractionated by gel filtration chromatography. J Proteome Res 2010, 9:5239-5249.
16. Oram J.F., Lawn R.M., Garvin M.R., Wade D.P. ABCA1 is the cAMP-inducible apolipoprotein receptor that mediates cholesterol secretion from macrophages. J Biol Chem 2000, 275:34508-34511.
17. Mott S., Yu L., Marcil M., Boucher B., Rondeau C., Genest J. Decreased cellular cholesterol efflux is a common cause of familial hypoalphalipoproteinemia: role of the ABCA1 gene mutations. Atherosclerosis 2000, 152:457-468.
18. Adorni M.P., Zimetti F., Billheimer J.T., Wang N., Rader D.J., Phillips M.C., et al. The roles of different pathways in the release of cholesterol from macrophages. J Lipid Res 2007, 48:2453-2462.
19. De la Llera-Moya M., Drazul-Schrader D., Asztalos B.F., Cuchel M., Rader D.J., Rothblat G.H. The ability to promote efflux via ABCA1 determines the capacity of serum specimens with similar high-density lipoprotein cholesterol to remove cholesterol from macrophages. Arterioscler Thromb Vasc Biol 2010, 30:796-801.
20. Quinn C.M., Williamson D., Hoekstra M., Lammers B., Out R., Hildebrand R.B., et al. Independent protective roles for macrophage Abcg1 and Apoe in the atherosclerotic lesion development. Atherosclerosis 2009, 205:420-426.
21. Stefulj J., Panzenboeck U., Becker T., Hirschmugl B., Schweinzer C., Lang I., et al. Human endothelial cells of the placental barrier efficiently deliver cholesterol to the fetal circulation via ABCA1 and ABCG1. Circ Res 2009, 104:600-608.
22. Van Eck M., Pennings M., Hoekstra M., Out R., Van Berkel T.J. Scavenger receptor BI and ATP-binding cassette transporter A1 in reverse cholesterol transport and atherosclerosis. Curr Opin Lipidol 2005, 16:307-315.
23. Zhang Y., McGillicuddy F.C., Hinkle C.C., O'Neill S., Glick J.M., Rothblat G.H., et al. Adipocyte Modulation of High-Density Lipoprotein Cholesterol. Circulation 2010, 121:1347-1355.
24. Larrede S., Quinn C.M., Jessup W., Frisdal E., Olivier M., Hsieh V., et al. Stimulation of cholesterol efflux by LXR agonists in cholesterol-loaded human macrophages is ABCA1-dependent but ABCG1-independent. Arterioscler Thromb Vasc Biol 2009, 29:1930-1936.
25. Yvan-Charvet L., Pagler T.A., Wang N., Senokuchi T., Brundert M., Li H., et al. SR-BI inhibits ABCG1-stimulated net cholesterol efflux from cells to plasma HDL. J Lipid Res 2008, 49:107-114.
26. Navab M., Ananthramaiah G.M., Reddy S.T., Van Lenten B.J., Ansell B.J., Fonarow G.C., et al. The oxidation hypothesis of atherogenesis: the role of oxidized phospholipids and HDL. J Lipid Res 2004, 45:993-1007.
27. Van Lenten B.J., Navab M., Shih D., Fogelman A.M., Lusis A.J. The role of high-density lipoproteins in oxidation and inflammation. Trends Cardiovasc Med 2001, 11:155-161.
28. Kontush A., Chapman M.J. Antiatherogenic function of HDL particle subpopulations: focus on antioxidative activities. Curr Opin Lipidol 2010, 21:312-318.
29. Zerrad-Saadi A., Therond P., Chantepie S., Couturier M., Rye K.A., Chapman M.J., et al. HDL3-Mediated Inactivation of LDL-Associated Phospholipid Hydroperoxides Is Determined by the Redox Status of Apolipoprotein A-I and HDL Particle Surface Lipid Rigidity: Relevance to Inflammation and Atherogenesis. Arterioscler Thromb Vasc Biol 2009, 29:2169-2175.
30. Girotti A.W. Translocation as a means of disseminating lipid hydroperoxide-induced oxidative damage and effector action. Free Radic Biol Med 2008, 44:956-968.
31. Panzenbock U., Stocker R. Formation of methionine sulfoxide-containing specific forms of oxidized high-density lipoproteins. Biochim Biophys Acta 2005, 1703:171-181.
32. Vila A., Korytowski W., Girotti A.W. Spontaneous intermembrane transfer of various cholesterol-derived hydroperoxide species: kinetic studies with model membranes and cells. Biochemistry 2001, 40:14715-14726.
33. Libby P. Inflammation in atherosclerosis. Nature 2002, 420:868-874.
34. Barter P.J., Nicholls S., Rye K.A., Anantharamaiah G.M., Navab M., Fogelman A.M. Antiinflammatory properties of HDL. Circ Res 2004, 95:764-772.
35. Murphy A.J., Chin-Dusting J.P., Sviridov D., Woollard K.J. The anti inflammatory effects of high density lipoproteins. Curr Med Chem 2009, 16:667-675.
36. Nicholls S.J., Dusting G.J., Cutri B., Bao S., Drummond G.R., Rye K.A., et al. Reconstituted high-density lipoproteins inhibit the acute pro-oxidant and proinflammatory vascular changes induced by a periarterial collar in normocholesterolemic rabbits. Circulation 2005, 111:1543-1550.
37. Yvan-Charvet L., Wang N., Tall A.R. Role of HDL, ABCA1, and ABCG1 transporters in cholesterol efflux and immune responses. Arterioscler Thromb Vasc Biol 2010, 30:139-143.
38. Baker P.W., Rye K.A., Gamble J.R., Vadas M.A., Barter P.J. Ability of reconstituted high density lipoproteins to inhibit cytokine-induced expression of vascular cell adhesion molecule-1 in human umbilical vein endothelial cells. J Lipid Res 1999, 40:345-353.
39. Recalde D., Ostos M.A., Badell E., Garcia-Otin A.L., Pidoux J., Castro G., et al. Human apolipoprotein A-IV reduces secretion of proinflammatory cytokines and atherosclerotic effects of a chronic infection mimicked by lipopolysaccharide. Arterioscler Thromb Vasc Biol 2004, 24:756-761.
40. Ashby D.T., Rye K.A., Clay M.A., Vadas M.A., Gamble J.R., Barter P.J. Factors influencing the ability of HDL to inhibit expression of vascular cell adhesion molecule-1 in endothelial cells. Arterioscler Thromb Vasc Biol 1998, 18:1450-1455.
41. Park C.T., Wright S.D. Fibrinogen is a component of a novel lipoprotein particle: factor H-related protein (FHRP) - associated lipoprotein particle (FALP). Blood 2000, 95:198-204.
42. Negre-Salvayre A., Dousset N., Ferretti G., Bacchetti T., Curatola G., Salvayre R. Antioxidant and cytoprotective properties of high-density lipoproteins in vascular cells. Free Radic Biol Med 2006, 41:1031-1040.
43. Terasaka N., Wang N., Yvan-Charvet L., Tall A.R. High-density lipoprotein protects macrophages from oxidized low-density lipoprotein-induced apoptosis by promoting efflux of 7-ketocholesterol via ABCG1. Proc Natl Acad Sci U S A 2007, 104:15093-15098.
44. Sugano M., Tsuchida K., Makino N. High-Density Lipoproteins Protect Endothelial Cells from Tumor Necrosis Factor-[alpha] - Induced Apoptosis. Biochem Biophys Res Commun. 2000, 272:872-876.
45. Mineo C., Yuhanna I.S., Quon M.J., Shaul P.W. High density lipoprotein-induced endothelial nitric-oxide synthase activation is mediated by Akt and MAP kinases. J Biol Chem 2003, 278:9142-9149.
46. Kimura T., Sato K., Malchinkhuu E., Tomura H., Tamama K., Kuwabara A., et al. High-Density Lipoprotein Stimulates Endothelial Cell Migration and Survival Through Sphingosine 1-Phosphate and Its Receptors. Arterioscler Thromb Vasc Biol 2003, 23:1283-1288.
47. Suc I., Escargueil-Blanc I., Troly M., Salvayre R., Negre-Salvayre A. HDL and ApoA prevent cell death of endothelial cells induced by oxidized LDL. Arterioscler Thromb Vasc Biol 1997, 17:2158-2166.
48. DeKroon R.M., Mihovilovic M., Goodger Z.V., Robinette J.B., Sullivan P.M., Saunders A.M., et al. ApoE genotype-specific inhibition of apoptosis. J Lipid Res 2003, 44:1566-1573.
49. Kimura T., Sato K., Kuwabara A., Tomura H., Ishiwara M., Kobayashi I., et al. Sphingosine 1-phosphate may be a major component of plasma lipoproteins responsible for the cytoprotective actions in human umbilical vein endothelial cells. J Biol Chem 2001, 276:31780-31785.
50. De Souza J.A., Vindis C., Negre-Salvayre A., Rye K.A., Couturier M., Therond P., et al. Small, dense HDL 3 particles attenuate apoptosis in endothelial cells: pivotal role of apolipoprotein A-I. J Cell Mol Med 2010, 14:608-620.
51. Davignon J., Ganz P. Role of endothelial dysfunction in atherosclerosis. Circulation 2004, 109:III27-III32.
52. Calabresi L., Gomaraschi M., Franceschini G. Endothelial protection by high-density lipoproteins: from bench to bedside. Arterioscler Thromb Vasc Biol 2003, 23:1724-1731.
53. Drew B.G., Fidge N.H., Gallon-Beaumier G., Kemp B.E., Kingwell B.A. High-density lipoprotein and apolipoprotein AI increase endothelial NO synthase activity by protein association and multisite phosphorylation. Proc Natl Acad Sci U S A 2004, 101:6999-7004.
54. Nofer J.R., van der Giet M., Tolle M., Wolinska I., von Wnuck Lipinski K., Baba H.A., et al. HDL induces NO-dependent vasorelaxation via the lysophospholipid receptor S1P3. J Clin Invest 2004, 113:569-581.
55. Terasaka N., Yu S., Yvan-Charvet L., Wang N., Mzhavia N., Langlois R., et al. ABCG1 and HDL protect against endothelial dysfunction in mice fed a high-cholesterol diet. J Clin Invest 2008, 118:3701-3713.
56. Cominacini L., Rigoni A., Pasini A.F., Garbin A.F., Davoli U., Campagn A., et al. The binding of oxidized low density lipoprotein (ox-LDL) to ox-LDL receptor-1 reduces the intracellular concentration of nitric oxide in endothelial cells through an increased production of superoxide. J Biol Chem 2001, 276:13750-13755.
57. Holy E.W., Besler C., Landmesser U., Luscher T.F., Tanner F.C. Abstract 5486: High Density Lipoprotein (HDL) From Healthy Subjects, but Not From Patients With Coronary Artery Disease, Exerts Anti-thrombotic Effects on Human Endothelial Cells. Circulation 2009, 120. S1100-a-.
58. Nofer J.R., Brodde M.F., Kehrel B.E. High-density lipoproteins, platelets and the pathogenesis of atherosclerosis. Clin Exp Pharmacol Physiol 2010, 37:726-735.
59. Oslakovic C., Krisinger M.J., Andersson A., Jauhiainen M., Ehnholm C., Dahlback B. Anionic phospholipids lose their procoagulant properties when incorporated into high density lipoproteins. J Biol Chem 2009, 284:5896-5904.
60. Desai K., Bruckdorfer K.R., Hutton R.A., Owen J.S. Binding of apo-Erich high density lipoprotein particles by saturable sites on human blood platelets inhibits agonist-induced platelet aggregation. J Lipid Res 1989, 30:831-840.
61. Lesnik P., Vonica A., Guerin M., Moreau M., Chapman M.J. Anticoagulant activity of tissue factor pathway inhibitor in human plasma is preferentially associated with dense subspecies of LDL and HDL and with Lp(a). Arterioscler Thromb 1993, 13:1066-1075.
62. Johnson J.D., Henriquez R.R., Tichy S.E., Russell D.H., McNeal C.J., Macfarlane R.D. UC/MALDI-MS analysis of HDL; evidence for density-dependent post-translational modifications. Int J Mass Spectrom 2007, 268:227-233.
63. Murch O., Collin M., Hinds C.J., Thiemermann C. Lipoproteins in inflammation and sepsis. I. Basic science. Intensive Care Med 2007, 33:13-24.
64. Levels J.H., Abraham P.R., van den Ende A., van Deventer S.J. Distribution and kinetics of lipoprotein-bound endotoxin. Infect Immun 2001, 69:2821-2828.
65. Li Y., Dong J.B., Wu M.P. Human ApoA-I overexpression diminishes LPS-induced systemic inflammation and multiple organ damage in mice. Eur J Pharmacol 2008, 590:417-422.
66. Berbee J.F., Mooijaart S.P., de Craen A.J., Havekes L.M., van Heemst D., Rensen P.C., et al. Plasma apolipoprotein CI protects against mortality from infection in old age. J Gerontol A Biol Sci Med Sci 2008, 63:122-126.
67. Thompson P.A., Gauthier K.C., Varley A.W., Kitchens R.L. ABCA1 promotes the efflux of bacterial LPS from macrophages and accelerates recovery from LPS-induced tolerance. Journal of Lipid Research 2010, 51:2672-2685.
68. Cai L., Ji A., de Beer F.C., Tannock L.R., van der Westhuyzen D.R. SR-BI protects against endotoxemia in mice through its roles in glucocorticoid production and hepatic clearance. J Clin Invest 2008, 118:364-375.
69. Perez-Morga D., Vanhollebeke B., Paturiaux-Hanocq F., Nolan D.P., Lins L., Homblé F., et al. Apolipoprotein L-I promotes trypanosome lysis by forming pores in lysosomal membranes. Science 2005, 309:469-472.
70. Molina-Portela M.P., Samanovic M., Raper J. Distinct roles of apolipoprotein components within the trypanosome lytic factor complex revealed in a novel transgenic mouse model. J Exp Med 2008, 205:1721-1728.
71. Hajduk S.L., Moore D.R., Vasudevacharya J., Siqueira J., Torri H., Tytl A.F., et al. Lysis of Trypanosoma brucei by a toxic subspecies of human high density lipoprotein. J Biol Chem 1989, 264:5210-5217.
72. Shiflett A.M., Bishop J.R., Pahwa A., Hajduk S.L. Human high density lipoproteins are platforms for the assembly of multi-component innate immune complexes. J Biol Chem 2005, 280:32578-32585.
73. Park C.T., Wright S.D. Plasma lipopolysaccharide-binding protein is found associated with a particle containing apolipoprotein A-I, phospholipid, and factor H-related proteins. J Biol Chem 1996, 271:18054-18060.
74. Drew B.G., Duffy S.J., Forbes J.M., Chin-Dusting J., Kaye D.M., Kemp B.E., et al. Abstract 1273: High Density Lipoprotein Modulates Glucose Metabolism by Multiple Mechanisms. Circulation 2009, 120. S468-c-9.
75. Von Eckardstein A., Sibler R.A. Possible contributions of lipoproteins and cholesterol to the pathogenesis of diabetes mellitus type 2. Curr Opin Lipidol 2011, 22:26-32.
76. Ortiz-Munoz G., Houard X., Martin-Ventura J.L., Ishida B.Y., Loyau S., Rossignol P., et al. HDL antielastase activity prevents smooth muscle cell anoikis, a potential new antiatherogenic property. Faseb J 2009, 23:3129-3139.
77. Salonen J.T., Salonen R., Seppanen K., Rauramaa R., Tuomilehto J. HDL, HDL2, and HDL3 subfractions, and the risk of acute myocardial infarction. A prospective population study in eastern Finnish men. Circulation 1991, 84:129-139.
78. Lamarche B., Moorjani S., Cantin B., Dagenais G.R., Lupien P.J., Despres J.P. Associations of HDL2 and HDL3 subfractions with ischemic heart disease in men. Prospective results from the Quebec Cardiovascular Study. Arterioscler Thromb Vasc Biol 1997, 17:1098-1105.
79. Stampfer M.J., Sacks F.M., Salvini S., Willett W.C., Hennekens C.H. A prospective study of cholesterol, apolipoproteins, and the risk of myocardial infarction. N Engl J Med 1991, 325:373-381.
80. Sweetnam P.M., Bolton C.H., Yarnell J.W., Bainton D., Baker I.A., Elwood, et al. Associations of the HDL2 and HDL3 cholesterol subfractions with the development of ischemic heart disease in British men. The Caerphilly and Speedwell Collaborative Heart Disease Studies. Circulation 1994, 90:769-774.
81. Yu S., Yarnell J.W., Sweetnam P., Bolton C.H. High density lipoprotein subfractions and the risk of coronary heart disease: 9-years follow-up in the Caerphilly Study. Atherosclerosis 2003, 166:331-338.
82. Williams P.T., Feldman D.E. Prospective study of coronary heart disease vs. HDL2, HDL3, and other lipoproteins in Gofman's Livermore Cohort. Atherosclerosis 2011, 214(1):196-202.
83. Asztalos B.F., Batista M., Horvath K.V., Cox C.E., Dallal G.E., Morse J.S., et al. Change in alpha1 HDL concentration predicts progression in coronary artery stenosis. Arterioscler Thromb Vasc Biol 2003, 23:847-852.
84. Asztalos B.F., Schaefer E.J. High-density lipoprotein subpopulations in pathologic conditions. Am J Cardiol 2003, 91:12E-E17.
85. Schaefer E.J., Asztalos B.F. Where are we with high-density lipoprotein raising and inhibition of cholesteryl ester transfer for heart disease risk reduction?. Curr Opin Cardiol 2007, 22:373-378.
86. Lamon-Fava S., Herrington D.M., Reboussin D.M., Sherman D.M., Horvath M., Cuppl K.V., et al. Plasma levels of HDL subpopulations and remnant lipoproteins predict the extent of angiographically-defined coronary artery disease in postmenopausal women. Arterioscler Thromb Vasc Biol 2008, 28:575-579.
87. Parra H.J., Arveiler D., Evans A.E., Cambou J.P., Amouyel P., Bingham A., et al. A case-control study of lipoprotein particles in two populations at contrasting risk for coronary heart disease. The ECTIM Study. Arterioscler Thromb 1992, 12:701-707.
88. Asztalos B., Zhang W., Roheim P.S., Wong L. Role of free apolipoprotein A-I in cholesterol efflux. Formation of pre-alpha-migrating high-density lipoprotein particles. Arterioscler Thromb Vasc Biol 1997, 17:1630-1636.
89. Asztalos B.F., Collins D., Cupples L.A., Demissie S., Horvath K.V., Bloomfield H.E., et al. Value of high-density lipoprotein (HDL) subpopulations in predicting recurrent cardiovascular events in the Veterans Affairs HDL Intervention Trial. Arterioscler Thromb Vasc Biol 2005, 25:2185-2191.
90. Montali A., Vega G.L., Grundy S.M. Concentrations of apolipoprotein A-I-containing particles in patients with hypoalphalipoproteinemia. Arterioscler Thromb 1994, 14:511-517.
91. Mora S., Szklo M., Otvos J.D., Greenland P., Psaty B.M., Goff, et al. LDL particle subclasses, LDL particle size, and carotid atherosclerosis in the Multi-Ethnic Study of Atherosclerosis (MESA). Atherosclerosis 2007, 192:211-217.
92. Festa A., Williams K., Hanley A.J.G., Otvos J.D., Goff D.C., Wagenknecht L.E., et al. Nuclear Magnetic Resonance Lipoprotein Abnormalities in Prediabetic Subjects in the Insulin Resistance Atherosclerosis Study. Circulation 2005, 111:3465-3472.
93. Rosenson R.S., Otvos J.D., Freedman D.S. Relations of lipoprotein subclass levels and low-density lipoprotein size to progression of coronary artery disease in the Pravastatin Limitation of Atherosclerosis in the Coronary Arteries (PLAC-I) trial. Am J Cardiol 2002, 90:89-94.
94. Smith J.D. Dysfunctional HDL as a Diagnostic and Therapeutic Target. Arterioscler Thromb Vasc Biol 2010, 30:151-155.
95. van der Westhuyzen D.R., de Beer F.C., Webb N.R. HDL cholesterol transport during inflammation. Curr Opin Lipidol 2007, 18:147-151.